HeartBeam (NASDAQ: BEAT), a medical technology company focused on cardiac care innovation, announced that it will host a conference call on May 13, 2026, at 4:30 p.m. Eastern time to discuss its first-quarter results for the period ended March 31, 2026. The call will also provide updates on key growth initiatives, including its limited commercial launch for arrhythmia assessment, extended-wear patch development, heart attack detection, and artificial intelligence programs.
The company, which received FDA clearance for its 3D ECG technology for arrhythmia assessment in December 2024 and for its 12-lead ECG synthesis software in December 2025, is positioning itself at the forefront of portable cardiac monitoring. HeartBeam's platform technology is designed to collect ECG signals in 3D from three non-coplanar directions and synthesize them into a 12-lead ECG, enabling physicians to identify cardiac health trends and acute conditions outside of medical facilities.
The earnings call will offer investors and analysts insight into the company's financial performance and progress toward commercializing its innovative cardiac monitoring solutions. HeartBeam holds over 20 issued patents related to its technology, underscoring its commitment to intellectual property protection and innovation in the cardiac care space.
For more details on the press release, visit this link. The latest news and updates relating to HeartBeam are available in the company's newsroom at https://ibn.fm/BEAT.
This announcement is significant as it provides a platform for HeartBeam to outline its strategic direction and operational milestones. The limited commercial launch for arrhythmia assessment marks a critical step toward bringing its cable-free, 3D ECG technology to market, potentially transforming how cardiac conditions are detected and monitored. The extended-wear patch development and AI programs further demonstrate the company's focus on expanding its product portfolio and leveraging advanced analytics to improve patient outcomes.
Forward-looking statements in the announcement are subject to risks and uncertainties, as detailed in the company's filings with the Securities and Exchange Commission. The full terms of use and disclaimers are available on the InvestorBrandNetwork website at http://IBN.fm/Disclaimer.
